Equities analysts predict that Steris PLC (NYSE:STE) will announce $1.11 earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Steris’ earnings, with the highest EPS estimate coming in at $1.12 and the lowest estimate coming in at $1.11. Steris reported earnings of $1.00 per share in the same quarter last year, which indicates a positive year over year growth rate of 11%. The firm is expected to report its next earnings results on Wednesday, August 14th.
According to Zacks, analysts expect that Steris will report full-year earnings of $5.38 per share for the current year, with EPS estimates ranging from $5.36 to $5.40. For the next year, analysts anticipate that the business will report earnings of $5.93 per share, with EPS estimates ranging from $5.90 to $5.99. Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Steris.
Steris (NYSE:STE) last announced its earnings results on Monday, May 13th. The medical equipment provider reported $1.53 earnings per share for the quarter, beating the consensus estimate of $1.44 by $0.09. Steris had a return on equity of 13.34% and a net margin of 10.93%. The company had revenue of $768.00 million for the quarter, compared to the consensus estimate of $738.87 million. During the same period last year, the business posted $1.24 EPS. The company’s revenue was up 7.3% on a year-over-year basis.
Several research analysts have weighed in on the company. KeyCorp lifted their target price on Steris from $135.00 to $138.00 and gave the company an “overweight” rating in a research note on Wednesday, May 15th. Zacks Investment Research downgraded Steris from a “hold” rating to a “sell” rating in a research note on Wednesday, April 24th. JMP Securities lifted their price target on Steris from $135.00 to $150.00 and gave the company a “market outperform” rating in a research note on Wednesday. Finally, Stephens lifted their price target on Steris from $135.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, May 15th. Five investment analysts have rated the stock with a buy rating, Steris presently has an average rating of “Buy” and a consensus price target of $148.20.
Shares of STE stock traded up $0.31 during midday trading on Friday, hitting $135.11. The company had a trading volume of 530,435 shares, compared to its average volume of 433,624. Steris has a 52-week low of $99.14 and a 52-week high of $137.60. The company has a market capitalization of $11.43 billion, a P/E ratio of 27.63 and a beta of 1.06. The company has a current ratio of 2.27, a quick ratio of 1.82 and a debt-to-equity ratio of 0.37.
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Wednesday, June 12th will be paid a $0.34 dividend. The ex-dividend date is Tuesday, June 11th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.01%. Steris’s dividend payout ratio (DPR) is presently 27.81%.
In related news, CEO Walter M. Rosebrough, Jr. sold 50,000 shares of Steris stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $125.00, for a total value of $6,250,000.00. Following the sale, the chief executive officer now directly owns 98,895 shares in the company, valued at $12,361,875. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Jacqueline B. Kosecoff sold 3,609 shares of Steris stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $132.22, for a total value of $477,181.98. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 60,351 shares of company stock worth $7,592,622. Company insiders own 2.38% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. boosted its position in Steris by 10.3% during the fourth quarter. BlackRock Inc. now owns 8,549,361 shares of the medical equipment provider’s stock worth $913,498,000 after purchasing an additional 800,900 shares in the last quarter. Vanguard Group Inc boosted its position in Steris by 1.8% during the third quarter. Vanguard Group Inc now owns 7,516,051 shares of the medical equipment provider’s stock worth $859,837,000 after purchasing an additional 133,510 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its position in Steris by 10,585.0% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 3,572,743 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 3,539,306 shares in the last quarter. WCM Investment Management LLC boosted its position in Steris by 0.8% during the first quarter. WCM Investment Management LLC now owns 2,382,799 shares of the medical equipment provider’s stock worth $302,656,000 after purchasing an additional 18,577 shares in the last quarter. Finally, Frontier Capital Management Co. LLC boosted its position in Steris by 7.8% during the fourth quarter. Frontier Capital Management Co. LLC now owns 1,158,334 shares of the medical equipment provider’s stock worth $123,768,000 after purchasing an additional 84,228 shares in the last quarter. Institutional investors own 82.81% of the company’s stock.
STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
See Also: Equity Income
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.